Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118629831> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2118629831 endingPage "437" @default.
- W2118629831 startingPage "434" @default.
- W2118629831 abstract "Ovarian clear cell adenocarcinoma is known to have poorer prognosis than ovarian serous cystadenocarcinoma. Cyclophosphamide plus cisplatin has been the standard therapy for ovarian cancer, but ovarian clear cell adenocarcinoma dose not respond to this therapy. The treatment for ovarian clear cell adenocarcinoma has not been established. We planned a pilot study of CPT-11 and cisplatin for the treatment of ovarian clear cell adenocarcinoma.First, three patients were administered 70 mg/m2 of cisplatin intravenously on day 1 and 60 mg/m2 of CPT-11 intravenously on days 1, 8 and 15. Treatment was repeated every 4 weeks. Other patients were administered 75 mg/m2 of cisplatin intraperitoneally on day 1 and 60 mg/m2 of CPT-11 intravenously on days 1, 8 and 15. Treatment was repeated every 4 weeks.A total of 10 patients were entered in this study and a total of 43 courses were administered. 1 CR, 1 PR and 1 PD were observed in patients with measurable lesion. Grade 3 leukopenia was experienced in seven patients, grade 3 thrombocytopenia in two and grade 3 anemia in five. Grade 3 liver toxicity was observed in one patient and grade 3 diarrhea in one patient. No grade 4 toxicity was experienced.CPT-11 plus cisplatin is feasible and has efficacy for ovarian clear cell adenocarcinoma. This regimen should be explored in a phase II study." @default.
- W2118629831 created "2016-06-24" @default.
- W2118629831 creator A5003132809 @default.
- W2118629831 creator A5010660159 @default.
- W2118629831 creator A5022302294 @default.
- W2118629831 creator A5031764973 @default.
- W2118629831 creator A5037231478 @default.
- W2118629831 creator A5039083958 @default.
- W2118629831 creator A5082508104 @default.
- W2118629831 creator A5087202055 @default.
- W2118629831 date "1999-09-01" @default.
- W2118629831 modified "2023-10-15" @default.
- W2118629831 title "A Pilot Study of CPT-11 and Cisplatin for Ovarian Clear Cell Adenocarcinoma" @default.
- W2118629831 cites W1827936231 @default.
- W2118629831 cites W1851083905 @default.
- W2118629831 cites W1959962586 @default.
- W2118629831 cites W2036743666 @default.
- W2118629831 cites W2048780683 @default.
- W2118629831 cites W2098822886 @default.
- W2118629831 cites W2142657147 @default.
- W2118629831 cites W2158553214 @default.
- W2118629831 cites W2328421677 @default.
- W2118629831 doi "https://doi.org/10.1093/jjco/29.9.434" @default.
- W2118629831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10563197" @default.
- W2118629831 hasPublicationYear "1999" @default.
- W2118629831 type Work @default.
- W2118629831 sameAs 2118629831 @default.
- W2118629831 citedByCount "26" @default.
- W2118629831 countsByYear W21186298312012 @default.
- W2118629831 countsByYear W21186298312014 @default.
- W2118629831 countsByYear W21186298312016 @default.
- W2118629831 countsByYear W21186298312017 @default.
- W2118629831 countsByYear W21186298312020 @default.
- W2118629831 countsByYear W21186298312023 @default.
- W2118629831 crossrefType "journal-article" @default.
- W2118629831 hasAuthorship W2118629831A5003132809 @default.
- W2118629831 hasAuthorship W2118629831A5010660159 @default.
- W2118629831 hasAuthorship W2118629831A5022302294 @default.
- W2118629831 hasAuthorship W2118629831A5031764973 @default.
- W2118629831 hasAuthorship W2118629831A5037231478 @default.
- W2118629831 hasAuthorship W2118629831A5039083958 @default.
- W2118629831 hasAuthorship W2118629831A5082508104 @default.
- W2118629831 hasAuthorship W2118629831A5087202055 @default.
- W2118629831 hasConcept C121608353 @default.
- W2118629831 hasConcept C126322002 @default.
- W2118629831 hasConcept C143998085 @default.
- W2118629831 hasConcept C2776694085 @default.
- W2118629831 hasConcept C2778239845 @default.
- W2118629831 hasConcept C2780427987 @default.
- W2118629831 hasConcept C2780873365 @default.
- W2118629831 hasConcept C2781182431 @default.
- W2118629831 hasConcept C2781413609 @default.
- W2118629831 hasConcept C29730261 @default.
- W2118629831 hasConcept C71924100 @default.
- W2118629831 hasConcept C90924648 @default.
- W2118629831 hasConceptScore W2118629831C121608353 @default.
- W2118629831 hasConceptScore W2118629831C126322002 @default.
- W2118629831 hasConceptScore W2118629831C143998085 @default.
- W2118629831 hasConceptScore W2118629831C2776694085 @default.
- W2118629831 hasConceptScore W2118629831C2778239845 @default.
- W2118629831 hasConceptScore W2118629831C2780427987 @default.
- W2118629831 hasConceptScore W2118629831C2780873365 @default.
- W2118629831 hasConceptScore W2118629831C2781182431 @default.
- W2118629831 hasConceptScore W2118629831C2781413609 @default.
- W2118629831 hasConceptScore W2118629831C29730261 @default.
- W2118629831 hasConceptScore W2118629831C71924100 @default.
- W2118629831 hasConceptScore W2118629831C90924648 @default.
- W2118629831 hasIssue "9" @default.
- W2118629831 hasLocation W21186298311 @default.
- W2118629831 hasLocation W21186298312 @default.
- W2118629831 hasOpenAccess W2118629831 @default.
- W2118629831 hasPrimaryLocation W21186298311 @default.
- W2118629831 hasRelatedWork W1448091729 @default.
- W2118629831 hasRelatedWork W1511187821 @default.
- W2118629831 hasRelatedWork W2053306150 @default.
- W2118629831 hasRelatedWork W2357273538 @default.
- W2118629831 hasRelatedWork W2361544313 @default.
- W2118629831 hasRelatedWork W2367148332 @default.
- W2118629831 hasRelatedWork W2392383546 @default.
- W2118629831 hasRelatedWork W2419081241 @default.
- W2118629831 hasRelatedWork W3149210031 @default.
- W2118629831 hasRelatedWork W4385496679 @default.
- W2118629831 hasVolume "29" @default.
- W2118629831 isParatext "false" @default.
- W2118629831 isRetracted "false" @default.
- W2118629831 magId "2118629831" @default.
- W2118629831 workType "article" @default.